Department of Gastrointestinal Surgery, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Department of Gastrointestinal Surgery, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Eur J Surg Oncol. 2020 Oct;46(10 Pt A):1963-1970. doi: 10.1016/j.ejso.2020.04.044. Epub 2020 May 4.
The survival impacts of the prognostic nutritional index (PNI) and sarcopenia have been separately investigated in patients with gastric carcinoma (GC), while the prognostic impact of the combination of them remains to be addressed.
In total, 1166 GC patients undergoing radical gastrectomy were retrospectively reviewed. A new prognostic score (PNIS) was developed based on preoperative PNI and sarcopenia; patients with both low PNI (≤44.8) and sarcopenia were allocated a score of 2, and those with only one or neither of these abnormalities were assigned a score of 1 or 0, respectively.
A lower PNI was independently associated with sarcopenia (P = 0.007). There were 704 (60.4%), 356 (30.5%) and 106 (9.1%) patients in the PNIS 0, 1 and 2 groups, respectively. A higher PNIS was associated with advanced age (P < 0.001) and a higher incidence of postoperative complications (P = 0.01). Patients with PNIS 2 showed significantly poorer overall survival (OS) than those with PNIS 1 or 0 (5-year OS; 57.8% vs. 79.2% vs. 91.6%, P < 0.001). Multivariate Cox hazards analysis showed PNIS 2 to be a powerful predictor of poor OS (HR 5.73, P < 0.001) in patients with pStage I disease, while not being independently associated with OS in those with pStage II/III disease. Patients with PNIS 2 had a markedly higher prevalence of non-GC-related death than those with scores of 0-1.
The scoring system combining PNI and sarcopenia is useful for predicting survival outcomes, especially non-GC-related death, in patients with early GC, a population with basically good oncological outcomes.
预后营养指数(PNI)和肌肉减少症已分别在胃癌(GC)患者中进行了生存影响研究,而两者结合的预后影响仍有待解决。
回顾性分析 1166 例接受根治性胃切除术的 GC 患者。基于术前 PNI 和肌肉减少症,制定了一种新的预后评分(PNIS);低 PNI(≤44.8)和肌肉减少症的患者分配得分为 2,只有一项或两项异常的患者分别分配得分为 1 或 0。
较低的 PNI 与肌肉减少症独立相关(P=0.007)。PNIS 0、1 和 2 组患者分别为 704 例(60.4%)、356 例(30.5%)和 106 例(9.1%)。较高的 PNIS 与年龄较大(P<0.001)和术后并发症发生率较高(P=0.01)相关。PNIS 2 患者的总生存(OS)明显低于 PNIS 1 或 0 患者(5 年 OS;57.8% vs. 79.2% vs. 91.6%,P<0.001)。多因素 Cox 风险分析显示,PNIS 2 是 pStage I 疾病患者 OS 的有力预测因子(HR 5.73,P<0.001),而在 pStage II/III 疾病患者中与 OS 无关。PNIS 2 患者非 GC 相关死亡的发生率明显高于评分 0-1 的患者。
该联合 PNI 和肌肉减少症的评分系统可用于预测早期 GC 患者的生存结局,尤其是非 GC 相关死亡,这是一类基本具有良好肿瘤学结局的人群。